Design makes a difference: A meta-analysis of antidepressant response rates in placebo-controlled versus comparator trials in late-life depression

American Journal of Geriatric Psychiatry

Volumn 16, Issue 1, 2008, Pages 65-73

  Sneed, Joel R ^a,b   Rutherford, Bret R ^a,b   Rindskopf, David ^c   Lane, David T ^b   Sackeim, Harold A ^a,b   Roose, Steven P ^a,b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^c CITY UNIVERSITY OF NEW YORK   (United States)

Author keywords

Antidepressants; Late life depression; Multilevel meta analysis; Randomized clinical trials

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; BUSPIRONE; CITALOPRAM; CLOMIPRAMINE; DOXEPIN; ESCITALOPRAM; FLUOXETINE; IMIPRAMINE; MIRTAZAPINE; NORTRIPTYLINE; PAROXETINE; PLACEBO; SERTRALINE; TRIMIPRAMINE; VENLAFAXINE;

ARTICLE; CLINICAL TRIAL; COCHRANE LIBRARY; CONTROLLED CLINICAL TRIAL; DEPRESSION; DRUG EFFICACY; HUMAN; MEDLINE; META ANALYSIS; METHODOLOGY; ONSET AGE; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW; TREATMENT RESPONSE; AGE; AGED; COMPARATIVE STUDY; REVIEW; STATISTICAL MODEL; TREATMENT OUTCOME;

AGE FACTORS; AGED; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; HUMANS; MODELS, STATISTICAL; PLACEBOS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 39749142205     PISSN: 10647481     EISSN: 15457214     Source Type: Journal    
DOI: 10.1097/JGP.0b013e3181256b1d     Document Type: Article

References (37)

1. Roose SP, Schatzberg AF: The efficacy of antidepressants in the treatment of late-life depression. Journal of Clinical Psychophar-macology 2005; 25(Supplement 1):S1-S7
2. Krell HV, Leuchter AF, Morgan M, Cook IA, Abrams M: Subject expectations of treatment effectiveness and outcome of treatment with an experimental antidepressant. Journal of Clinical Psychiatry 2004; 65:1174-1179
3. Roose SP, Sackeim HA: Antidepressant medication for the treatment of late-life depression, in Late-life depression. Edited by Roose SP, Sackeim HA, Oxford University Press, 2004, pp 192-202
4. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Strupp DF, Stroup DF, Group Q: Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. The Lancet 1999; 354:1896-1900
5. Falk W, Rosenbaum J, Otto M, Zusky P, Weilburg J, Nixon R: Fluoxetine versus trazodone in depressed geriatric patients. Journal of Geriatric Psychiatry and Neurology. 1989; 2:208- 214
6. Fairweather DB, Kerr JS, Harrison DA, Moon CA: A double blind comparison of the effects of fluoxetine and amitriptyline on cognitive function in elderly depressed patients. Human Psycho-pharmacology 1993; 8:41-47
7. Dunner DL, Cohn JB, Walshe T, 3rd, Cohn CK, Feighner JP, Fieve RR, Halikas JP, Hartford JT, Hearst ED, Settle EC, Jr., et al.: Two combined, multicenter double-blind studies of paroxetine and doxepin in geriatric patients with major depression. Journal of Clinical Psychiatry 1992; 53:57-60
8. Kasper S, de Swart H, Andersen H, F.: Escitalopram in the treatment of depressed elderly patients. American of Geriatric Psychiatry 2005; 13:884-891
9. Rapaport MH, Schneider LS, Dunner DL, Davies JT, Pitts CD: Efficacy of controlled-release paroxetine in the treatment of late-life depression. Journal of Clinical Psychiatry 2003; 64(9): 1065-1074
10. Roose SP, Sackeim HA, Krishnan KRR, Pollock BG, Alexopoulos G, Lavretsky HK, I., Hakkarainen RH: Antidepressant pharmaco-therapy in the treatment of depression in the very old: A randomized, placebo-controlled trial. American Journal of Psychiatry 2004; 161(11):2050-2059
11. Schatzberg A, Roose S: A double-blind, placebo-controlled study of venlafaxine and fluoxetine in geriatric outpatients with major depression. American Journal of Geriatric Psychiatry 2006; 14: 361-370
12. Schneider LS, Nelson JC, Clary CM, Newhouse P, Krishnan KR, Shiovitz T, Weihs K, Sertraline Elderly Depression Study G: An 8-week multicenter, parallel-group, double-blind, placebo-controlled study of sertraline in elderly outpatients with major depression. [see comment]. American Journal of Psychiatry 2003; 160(7):1277-85
13. Schweizer E, Rickels K, Hassman H, Garcia-Espana F: Buspirone and imipramine for the treatment of major depression in the elderly. Journal of Clinical Psychiatry 1998; 59(4):175-83
14. Tollefson GD, Bosomworth JC, Heiligenstein JH, Potvin JH, Hol-man S: A double-blind, placebo-controlled clinical trial of fluox-etine in geriatric patients with major depression. The Fluoxetine Collaborative Study Group. International Psychogeriatrics 1995; 7(1):89-104
15. Bondareff W, Alpert M, Friedhoff AJ, Richter EM, Clary CM, Batzar E: Comparison of sertraline and nortriptyline in the treatment of major depressive disorder in late life. American Journal of Psychiatry 2000; 157(5):729-36
16. Feighner JP, Cohn JB: Double-blind comparative trials of fluox-etine and doxepin in geriatric patients with major depressive disorder. Journal of Clinical Psychiatry 1985; 46(3 Pt 2):20-5
17. Forlenza OV, Almeida OP, Stoppe A, Jr., Hirata ES, Ferreira RCR: Antidepressant efficacy and safety of low-dose sertraline and standard-dose imipramine for the treatment of depression in older adults: results from a double-blind, randomized, controlled clinical trial. International Psychogeriatrics 2001; 13(1):75-84
18. Guillibert E, Pelicier Y, Archambault JC, Chabannes JP, Clerc G, Desvilles M, Guibert M, Pagot R, Poisat JL, Thobie Y: A double-blind, multicentre study of paroxetine versus clomipramine in depressed elderly patients. Acta Psychiatrica Scandinavica, Supplementum 1989; 350:132-4
19. Hutchinson DR, Tong S, Moon CA, Vince M, Clarke A: Paroxetine in the treatment of elderly depressed patients in general practice: a double-blind comparison with amitriptyline. International Clinical Psychopharmacology 1992; 4:43-51
20. Nair NP, Amin M, Schwartz G, Dastoor D, Thavundayil JX, Mirmi-ran J, MacDonald C, Phillips R: A comparison of the cardiac safety and therapeutic efficacy of trimipramine versus doxepin in geriatric depressed patients. Journal of the American Geriatrics Society 1993; 41(8):863-7
21. Newhouse PA, Krishnan KR, Doraiswamy PM, Richter EM, Batzar ED, Clary CM: A double-blind comparison of sertraline and flu-oxetine in depressed elderly outpatients. Journal of Clinical Psychiatry 2000; 61(8):559-68
22. Schatzberg AF, Kremer C, Rodrigues HE, Murphy GM, Jr., Mir-tazapine vs. Paroxetine Study G: Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients. American Journal of Geriatric Psychiatry 2002; 10(5): 541-50
23. Weihs KL, Settle EC, Jr., Batey SR, Houser TL, Donahue RM, Ascher JA: Bupropion sustained release versus paroxetine for the treatment of depression in the elderly. [see comment]. Journal of Clinical Psychiatry 2000; 61(3):196-202
24. Bryk AS, Raudenbush SW: Hierarchical linear models. Newbury Park, CA, Sage Publications, 1992
25. Hox J: Multilevel Analysis: Techniques and applications. Mah-wah, NJ, Lawrence Erlbaum Publishers, 2002
26. Haddock CK, Rindskopf D, Shadish WR: Using odds ratios as effect sizes for meta-analysis of dichotomous data: A primer on methods and issues. Psychological Methods 1998; 3:339-353
27. Benedetti F, Mayberg HS, Wager TD, Stohler CS, Zubieta J-K: Neurobiological mechanisms of teh placebo effect. Journal of Neuroscience 2005; 25:10390- 10402
28. de la Fuente-Fernandez R, Schulzer M, Stoessl AJ: Placebo mechanisms and reward circuitry: Clues from Parkinson's disease. Biological Psychiatry 2004; 56:67-71
29. Colloca L, Lopiano L, Lanotte M, F. B: Overt versus covert treatment for pain, anxiety, and Parkinson's disease. Lancet Neurology 2004; 3:679-684
30. Volkow ND, Wang GJ, Ma Y, Fowler JS, Zhu W, Maynard L, Telang F, Vaska P, Ding YS, Wong C, Swanson JM: Expectation enhances the regional brain metabolic and the reinforcing effects of stimulants in cocaine abusers. Journal of Neuroscience 2003; 23:11461-11468
31. Volkow ND, Wang GJ, Ma Y, Fowler JS, Wong C, Jayne M, Telang F, Swanson JM: Effects of expectation on the brain metabolic responses to methylphenidate and to its placebo in non-drug abusing subjects. Neuroimage 2006; 32:1782-92
32. Preston C, Ashby D, Smyth R: Adjusting for publication bias: Modelling the selectio process. Journal of Evaluation and in Clinical Practice 2004; 10:313-322
33. Slavin RE: Best evidence synthesis: An intelligent alternative to meta-analysis. Journal of Clinical Epidemiology 1995; 48:9-18
34. Hox JJ, De Leeuw ED: A comparison of nonresponse in mail, telephone, and face-to-face surveys: Applied multilevel modeling to meta-analysis. Quality and Quantity 1994; 28:329-344
35. Wilson K, Mottram P, Sivanranthan A, Nightingale A: Antidepres-sants versus placebo for the depressed elderly [Systematic Review]. Cochrane Database of Systematic Reviews 2005; 4:4
36. Pinquart M, Duberstein PR, Lyness JM: Treatments for later-life depressive conditions: A meta-analytic comparison of pharmaco-therapy and psychotherapy. American Journal of Psychiatry 2006
37. Mottram P, Wilson K, Strobl J: Antidepressants for depressed elderly. Cochrane Database of Systematic Reviews 2006